275 related articles for article (PubMed ID: 28695301)
1. Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis.
van Helden EJ; Menke-van der Houven van Oordt CW; Heymans MW; Ket JCF; van den Oord R; Verheul HMW
Cancer Metastasis Rev; 2017 Jun; 36(2):395-406. PubMed ID: 28695301
[TBL] [Abstract][Full Text] [Related]
2. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.
Chan DLH; Segelov E; Wong RS; Smith A; Herbertson RA; Li BT; Tebbutt N; Price T; Pavlakis N
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007047. PubMed ID: 28654140
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of anti-EGFR monoclonal antibodies combined with different chemotherapy regimens in patients with RAS wild-type metastatic colorectal cancer: A meta-analysis.
Sun H; Li Y; Su Y; Wu X; Zhou X; Han J; Li J
J Evid Based Med; 2019 Nov; 12(4):300-312. PubMed ID: 31596544
[TBL] [Abstract][Full Text] [Related]
5. Which is false: oxaliplatin or fluoropyrimidine? An analysis of patients with KRAS wild-type metastatic colorectal cancer treated with first-line epidermal growth factor receptor monoclonal antibody.
Wen F; Tang R; Sang Y; Li M; Hu Q; Du Z; Zhou Y; Zhang P; He X; Li Q
Cancer Sci; 2013 Oct; 104(10):1330-8. PubMed ID: 23822592
[TBL] [Abstract][Full Text] [Related]
6. No survival benefit from adding cetuximab or panitumumab to oxaliplatin-based chemotherapy in the first-line treatment of metastatic colorectal cancer in KRAS wild type patients: a meta-analysis.
Zhou SW; Huang YY; Wei Y; Jiang ZM; Zhang YD; Yang Q; Xie DR
PLoS One; 2012; 7(11):e50925. PubMed ID: 23226426
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis from 12 randomized controlled trials.
Lv ZC; Ning JY; Chen HB
Tumour Biol; 2014 Dec; 35(12):11741-50. PubMed ID: 25417200
[TBL] [Abstract][Full Text] [Related]
8. Role of Anti-Epidermal Growth Factor Receptor Therapy Compared with Anti-Vascular Endothelial Growth Factor Therapy for Metastatic Colorectal Cancer: an Update Meta-Analysis of Randomized Clinical Trials.
Wang JX; Wu HL; Zhu M; Zhou R
Pathol Oncol Res; 2020 Jan; 26(1):159-166. PubMed ID: 29383654
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy With or Without Anti-EGFR Agents in Left- and Right-Sided Metastatic Colorectal Cancer: An Updated Meta-Analysis.
Wang ZX; Wu HX; He MM; Wang YN; Luo HY; Ding PR; Xie D; Chen G; Li YH; Wang F; Xu RH
J Natl Compr Canc Netw; 2019 Jul; 17(7):805-811. PubMed ID: 31319395
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
Arnold D; Lueza B; Douillard JY; Peeters M; Lenz HJ; Venook A; Heinemann V; Van Cutsem E; Pignon JP; Tabernero J; Cervantes A; Ciardiello F
Ann Oncol; 2017 Aug; 28(8):1713-1729. PubMed ID: 28407110
[TBL] [Abstract][Full Text] [Related]
11. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
Chan DL; Pavlakis N; Shapiro J; Price TJ; Karapetis CS; Tebbutt NC; Segelov E
PLoS One; 2015; 10(8):e0135599. PubMed ID: 26275292
[TBL] [Abstract][Full Text] [Related]
12. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.
Sorich MJ; Wiese MD; Rowland A; Kichenadasse G; McKinnon RA; Karapetis CS
Ann Oncol; 2015 Jan; 26(1):13-21. PubMed ID: 25115304
[TBL] [Abstract][Full Text] [Related]
13. Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis.
Vale CL; Tierney JF; Fisher D; Adams RA; Kaplan R; Maughan TS; Parmar MK; Meade AM
Cancer Treat Rev; 2012 Oct; 38(6):618-25. PubMed ID: 22118887
[TBL] [Abstract][Full Text] [Related]
14. Antiepidermal growth factor receptor monoclonal antibody improves survival outcomes in the treatment of patients with metastatic colorectal cancer.
Wang L; Chen X; Li W; Sheng Z
Anticancer Drugs; 2012 Feb; 23(2):155-60. PubMed ID: 21955998
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
16. Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of randomized studies.
Cui D; Cao D; Yang Y; Qiu M; Huang Y; Yi C
Mol Biol Rep; 2014 Mar; 41(3):1291-8. PubMed ID: 24390240
[TBL] [Abstract][Full Text] [Related]
17. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.
Kang MJ; Hong YS; Kim KP; Kim SY; Baek JY; Ryu MH; Lee JL; Chang HM; Kim MJ; Chang HJ; Kang YK; Kim TW
Invest New Drugs; 2012 Aug; 30(4):1607-13. PubMed ID: 21706149
[TBL] [Abstract][Full Text] [Related]
18. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
19. First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis.
Pietrantonio F; Cremolini C; Petrelli F; Di Bartolomeo M; Loupakis F; Maggi C; Antoniotti C; de Braud F; Falcone A; Iacovelli R
Crit Rev Oncol Hematol; 2015 Oct; 96(1):156-66. PubMed ID: 26088456
[TBL] [Abstract][Full Text] [Related]
20. Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database.
Karapetis CS; Liu H; Sorich MJ; Pederson LD; Van Cutsem E; Maughan T; Douillard JY; O'Callaghan CJ; Jonker D; Bokemeyer C; Sobrero A; Cremolini C; Chibaudel B; Zalcberg J; Adams R; Buyse M; Peeters M; Yoshino T; de Gramont A; Shi Q
Br J Cancer; 2024 May; 130(8):1269-1278. PubMed ID: 38402342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]